Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/ vasopressin receptors

British Journal of Pharmacology

Volumn 125, Issue 4, 1998, Pages 803-811

  Chan, W Y ^a   Wo, N C ^a   Stoev, S ^b   Cheng, L L ^b   Manning, M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Hypotensive vasopressin peptides; Nitric oxide and vasopressin analogues; Selective hypotensive vasopressin analogue agonists; Vasodilating action of AVP

Indexed keywords

ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; BRADYKININ B2 RECEPTOR; CHOLINERGIC RECEPTOR; N(G) NITROARGININE METHYL ESTER; OXYTOCIN RECEPTOR; PROSTAGLANDIN; VASOPRESSIN; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BIOASSAY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; NEUROHYPOPHYSIS; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; RECEPTOR BLOCKING;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARGININE VASOPRESSIN; AUTONOMIC DENERVATION; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PEPTIDES; PITUITARY GLAND, POSTERIOR; PROSTAGLANDINS; RATS; RATS, WISTAR; RECEPTORS, BRADYKININ; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; TIME FACTORS; VASOPRESSINS;

EID: 0031760550     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702114     Document Type: Article

References (46)

1. ALTURA, B.M. & ALTURA, B.T. (1977). Vascular smooth muscle and neurohypophyseal hormones. Fed. Proc., 36, 1853-1860.
2. BICHET, D.G., RAZI, M., LONGERGAN, M., ARTHUS, M.-F., PEPUKNA, V., KORTAS, C. & BARJON, J.-N. (1988). Hemodynamic and coagulation responses to 1-deamino[8-D-arginine]vasopressin in patients with congenital nephrogenic diabetes insipidus. New Eng. J. Med., 318, 881-887.
3. COWLEY Jr. A.W., MERRILL, D., OSBORN, J. & BARBER, B.J. (1984). Influence of vasopressin and angiotensin on baroreflexes in the dog. Cir. Res., 54, 163-172.
4. CHAN, W.Y. (1983). Uterine and placental prostaglandins and their modulation of oxytocin sensitivity and contractility in the parturient uterus. Biol. Reprod., 29, 680-688.
5. CHAN, W.Y., WO, N.C., STOEV, S., CHENG, L.L. & MANNING, M. (1998). Discovery of novel selective hypotensive vasopressin peptides: A new vasodilating vasopressin receptor? In: Vasopressin and oxytocin: synopsis of recent advances in molecular, cellular and clinical research. Zingg, H.H., Bichet, D.G. & Bourque, C. (eds). (in press), Plenum: New York.
6. DEKANSKI, J. (1952). The quantitative assays of vasopressin. Br. J. Pharmacol., 7, 567-572.
7. DWORKIN, M.J., CARNOCHAN, P. & ALLEN-MERSH, T.G. (1995). Nitric oxide inhibition sustains vasopressin-induced vasoconstriction. Br J. Cancer, 71, 942-944.
8. DYKES, D.F., NESTOR Jr J.J., FERGER, M.F. & DU VIGNEUAD, V. (1974). [1-β-Mercapto-β,β-diethylpropionic acid]-8-arginine-vasopressin, a potent inhibitor of 8-lysinevasopressin and oxytocin. J. Med. Chem., 17, 250-252.
9. 9]-OVT: A selective oxytocin receptor ligand. Eur. J. Pharmacol., 147, 197-207.
10. GARCIA-VILLALON, A.L., GARCIA, J.L., FERNANDEZ, N., MONGE, L., GOMEZ, B. & DIEGUEZ, G. (1996). Regional difference in the arterial response to vasopressin: role of endothelial nitric oxide. Br. J. Pharmacol., 118, 1848-1854.
11. HIRATA, Y., HAYAKAWA, H., KAKOKI, M., TOJO, A., SUZUKI, E., NAGATA, D., KIMURA, K., GOTO, A., KIKUCHI, K., NAGANO, T., HIROBE, M. & OMATA, M. (1997). Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney. Hypertension, 29, 58-64.
12. HOLTON, P. (1948). A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol., 3, 328-334.
13. 1-receptor antagonism in baroreflex-deficient subjects. Am. J. Physol., 268, R156-R163.
14. JARD, S., BARBERIS, C., AUDIGIER, S. & TRIBOLLET, E. (1987). Neurohypophysial hormone receptor systems in brain and periphery. Prog. Brain Res., 72, 173-187.
15. KATUSIC, Z.S., SHEPHERD, J.T. & VANHOUTTE, P.M. (1986). Oxytocin causes endothelium-dependent relaxation of canine basilar arteries by activating V1 - vasopressinergic receptors. J. Pharmacol. Exp. Ther., 236, 166-170.
16. KIM, P., KATUSIC, Z.S. & VANHOUTTE, P.M. (1988). Endothelium-dependent responses to arginine vasopressin. In: Vasopressin: cellular and integrative, functions. Cowley Jr, A. W., Liard, J.-F. & Ausiello, D.A. (eds). Raven Press: New York. pp. 455-459.
17. KRUSZYNSKI, M., LAMMEK, B., MANNING, M., SETO, J., HALDAR, J. & SAWYER, W.H. (1980). [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid),2-(O-methyl)-tyrosine]-arginine-vasopressin and [1-(β-mercapto-β,β-cyclopentamethylene-propionic acid)]arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine vasopressin. J. Med. Chem., 23, 364-368.
18. LANDRY, D.W., LEVIN, H.R., GALLANT, E.M., ASHTON Jr R.C., SEO, S., D'ALESSANDRO, D., OZ, M.C., & OLIVER, J.A. (1997). Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation, 95, 1122-1125.
19. LIARD, J.-F. (1988). Characterization of acute hemodynamic effects of antidiuretic agonists in conscious dogs. J. Cardiovasc. Pharmacol., 11, 174-180.
20. 2-induced vasodilation in dogs. Am. J. Physiol., 266, H99-H106.
21. MANNING, M., CHENG, L.L., STOEV, S., KLIS, W.A., NAWROCKA, E., OLMA, A., SAWYER, W.H., WO, N.C. & CHAN, W.Y. (1997). Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists. J. Peptide Sci., 3, 31-46.
22. MANNING, M., KRUSZYNSKI, M., BANKOWSKI, K., OLMA, A., LAMMEK, B., CHENG, L.L., KLIS, W.A., SETO, J., HALDAR, J. & SAWYER, W.H. (1989). Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. J. Med. Chem., 32, 382-391.
23. MANNING, M., OLMA, A., KLIS, W.A., KOLODZIEJCZYK, A., SETO, J. & SAWYER, W.H. (1982). Design and synthesis of more potent antagonists of the antidiuretic responses to arginine vasopressin. J. Med. Chem., 25, 45-50.
24. MANNING, M., STOEV, S., WO, N.C. & CHAN, W.Y. (1998). Discovery of novel selective hypotensive analogues of a vasopressin antagonist. In: Peptides 1996. Ramage, R. & Epton, R. (eds). Mayflower Scientific Ltd: England. pp. 615-616.
25. MERRIFIELD, R.B. (1964). Solid-phase peptide synthesis. III. An improved synthesis of bradykinin. Biochem., 9, 1385-1390.
26. MICHELL, R.H., KIRK, C.J. & BILLAH, M.M. (1979). Hormone stimulation of phosphatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans., 7, 861-865.
27. MUNSICK, R.A. (1960). Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology, 66, 451-457.
28. 2 receptors in conscious dogs. Am. J. Physiol., 265, R934-R942.
29. 2 receptors. Am. J. Physiol., 269, R193-R200.
30. NAKANO, J. & FISHER, R.D. (1963). Studies on the cardiovascular effects of synthetic oxytocin. J. Pharmacol. Exp. Ther., 142, 206-214.
31. OKAMURA, T., TODO, M., AYAJIKI, K. & TODA, N. (1997). Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J. Vas. Res., 34, 464-472.
32. REID, I.A. (1997). Role of vasopressin deficiency in the vasodilation of septic shock. Circulation, 95, 1108-1110.
33. REID, I.A. & SCHWARTZ, J. (1984). Role of vasopressin in the control of blood pressure. In: Frontiers in neuroendocrinology. Martini, L. & Ganong, W.F. (eds). pp. 177-197. Raven Press: New York.
34. RUDICHENKO, V.M & BEIERWALTES, W.H. (1995). Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J. Vasc. Res., 32, 100-105.
35. SAWYER, W.H. (1961). Biologic assays for oxytocin and vasopressin. Methods Med. Res., 9, 210-219.
36. SAWYER, W.H. & MANNING, M. (1973). Synthetic analogs of oxytocin and the vasopressins. Ann. Rev. Pharmacol., 13, 5-17.
37. SCHILD, H.O. (1947). pA, a new scale for the measurement of drug antagonism. Br. J. Pharmacol., 2, 189-206.
38. SCHWARTZ, J. & REID, I.A. (1983). Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology, 112, 234-238.
39. SHARE, L. (1988). Role of vasopressin in cardiovascular regulation. Physiol. Rev., 68, 1248-1284.
40. 2 receptors in conscious rats. Am. J. Physiol., 264, R345-R349.
41. STEWART, J.M., GERA, L., HANSON, W., ZUZACK, J.S., BURKARD, M., MCCULLOUGH, R. & WHALLEY, E.T. (1996). A new generation of bradykinin antagonists. Immunopharmacol., 33, 51-60.
42. STEWART, J.M. & YOUNG, J.D. (1984). Solid Phase Peptide Synthesis. Rockford, IL: Pierce Chemical Co.
43. 2 receptor-mediated vasodilation in healthy humans. J. Cardiovasc. Pharmacol., 25, 387-392.
44. 2 receptor defect. J. Hypertension, 13, 1695-1700.
45. WEBB, R.L., OSBORN Jr, J.W. & COWLEY JR, A.W. (1986). Cardiovascular actions of vasopressin: baroreflex modulation in the conscious rat. Am. J. Physiol., 251, H1244-H1251.
46. YAMADA, K., NAKAYMA, M., NAKANO, H., MIMURA, N. & YOSHIDA, S. (1993). Endothelium-dependent vasorelaxation evoked by desmopressin and involvement of nitric oxide in rat aorta. Am. J. Physiol., 264, E203-E207.